SYM Financial Corp
NBIX icon

SYM Financial Corp’s Neurocrine Biosciences NBIX Stock Holding History

SYM Financial Corp’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-1,207
Closed -$203K – 577
2026
Q2 		$203K Sell
1,207
-735
-38% -$109K 0.02% 379
2026
Q1 		$256K Sell
1,942
-97
-5% -$12.9K 0.03% 252
2025
Q4 		$289K Buy
2,039
+281
+16% +$40.7K 0.03% 234
2025
Q3 		$247K Buy
+1,758
New +$238K 0.03% 259

Other funds holding NBIX

Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $61B AUM 26.92% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $118B AUM 40.52% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Ninety One (UK)
Ninety One (UK) London, United Kingdom $45.5B AUM 15.2% 1-Year Est. Return
KBC Group
KBC Group Brussels, Belgium $47.9B AUM 37.61% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Seizert Capital Partners
Seizert Capital Partners Birmingham, Michigan $2.3B AUM 16.06% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $87.8B AUM 20.94% 1-Year Est. Return
Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return

SYM Financial Corp's NBIX Position: Q3 2026 in Review

SYM Financial Corp sold out of Neurocrine Biosciences (NBIX) in Q3 2026, closing a stake of 1,207 shares — an estimated $203K sold.

SYM Financial Corp first reported a position in NBIX in Q3 2025 and held it in 4 quarters. The position peaked at $289K in Q4 2025. 333 funds tracked by Wall St. Rank hold NBIX as of Q3 2026.

  • SYM Financial Corp reported no remaining Neurocrine Biosciences position as of Q3 2026 after selling out during the quarter.
  • SYM Financial Corp sold 1,207 Neurocrine Biosciences shares in Q3 2026, an estimated $203K.
  • SYM Financial Corp first reported a position in Neurocrine Biosciences in Q3 2025 and held it in 4 quarters.
  • SYM Financial Corp's Neurocrine Biosciences position peaked at $289K in Q4 2025.
  • 333 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2026.

Based on SYM Financial Corp's 13F filing for Q3 2026, filed 26 Oct 2026.